<DOC>
	<DOCNO>NCT02528617</DOCNO>
	<brief_summary>The purpose trial study effect Velaglucerase Alfa skeletal bone development child Type 1 Type 3 Gaucher Disease . In addition , natural history neurological status child Type 3 Gaucher Disease study .</brief_summary>
	<brief_title>The Effect Velaglucerase Alfa ( Vpriv ) Skeletal Development Pediatric Gaucher Disease</brief_title>
	<detailed_description />
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Enzyme Replacement Therapy naive , confirmed diagnosis Gaucher disease type 1 3 , able travel Dallas , Texas 1x per year baseline plus 3 consecutive year , able tolerate study procedure , skeleton fully form confirm DXA MRI ) , willing receive velaglucerase alfa infusion every week duration study . Clinically unstable , take take bisphosphonates , Gaucher type 2 , pregnant female , deem inappropriate participation principal investigator .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>